We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$25.4B
1-Year Est. Return
38.46%
This Fund
S&P 500
This Quarter
Est. Return
+13.16%
1 Year Est. Return
+38.46%
3 Year Est. Return
+154.38%
5 Year Est. Return
+223.79%
10 Year Est. Return
+923.25%
AUM
$22.5B
AUM Growth
+$1.93B
(+9.4%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
26.61%
Holding
1,346
New
164
Increased
337
Reduced
605
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$426M |
| 2 |
Deere & Co
DE
|
+$212M |
| 3 |
NVIDIA
NVDA
|
+$149M |
| 4 |
W.W. Grainger
GWW
|
+$140M |
| 5 |
Netflix
NFLX
|
+$135M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$196M |
| 2 |
Home Depot
HD
|
+$189M |
| 3 |
Gilead Sciences
GILD
|
+$145M |
| 4 |
Oracle
ORCL
|
+$145M |
| 5 |
Microsoft
MSFT
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.24% |
| 2 | Financials | 13.5% |
| 3 | Healthcare | 12.02% |
| 4 | Consumer Discretionary | 11.94% |
| 5 | Industrials | 11.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Adaptive Biotechnologies
ADPT
$4.02B
| $191K | ﹤0.01% |
21,646
+1,593
| +8% | +$14K |
|
|
AUD
1127
DELISTED
Audacy, Inc.
AUD
| $186K | ﹤0.01% |
1,381,636
+276,126
| +25% | +$63.5K |
|
1128
Kinder Morgan
KMI
$70.7B
| $184K | ﹤0.01% |
10,481
-1,225,160
| -99% | -$21.8M |
|
1129
Target Hospitality
TH
$1.61B
| $180K | ﹤0.01% |
13,687
-52,112
| -79% | -$834K |
|
1130
Twist Bioscience
TWST
$7.85B
| $174K | ﹤0.01% |
11,570
+433
| +4% | +$9.56K |
|
1131
Maravai LifeSciences
MRVI
$861M
| $171K | ﹤0.01% |
12,219
| – | – |
|
1132
Warner Bros
WBD
$69.3B
| $168K | ﹤0.01% |
11,150
-699
| -6% | -$9.95K |
|
1133
American Airlines Group
AAL
$9.88B
| $165K | ﹤0.01% |
11,157
| – | – |
|
1134
AGNC Investment
AGNC
$12.9B
| $153K | ﹤0.01% |
15,157
+126
| +0.8% | +$1.37K |
|
|
TELL
1135
DELISTED
Tellurian Inc.
TELL
| $150K | ﹤0.01% |
122,285
-10,383
| -8% | -$16.5K |
|
|
RTL
1136
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $136K | ﹤0.01% |
21,720
| – | – |
|
1137
ACV Auctions
ACVA
$1.32B
| $134K | ﹤0.01% |
10,387
-505
| -5% | -$5.52K |
|
1138
JetBlue
JBLU
$2.18B
| $118K | ﹤0.01% |
16,174
| – | – |
|
1139
FuelCell Energy
FCEL
$1.73B
| $116K | ﹤0.01% |
1,354
-108
| -7% | -$10.6K |
|
1140
Accel Entertainment
ACEL
$1B
| $109K | ﹤0.01% |
11,921
| – | – |
|
|
UNIT
1141
Uniti Group
UNIT
$2.31B
| $88.7K | ﹤0.01% |
24,996
-46,747
| -65% | -$248K |
|
1142
Rithm Capital
RITM
$5.71B
| $87.6K | ﹤0.01% |
10,948
| – | – |
|
1143
Uranium Energy
UEC
$5.62B
| $85.1K | ﹤0.01% |
29,545
-71,196
| -71% | -$258K |
|
1144
LivePerson
LPSN
$34.1M
| $75.3K | ﹤0.01% |
1,139
+126
| +12% | +$20.2K |
|
|
SWN
1145
DELISTED
Southwestern Energy Company
SWN
| $58.8K | ﹤0.01% |
11,755
-10,688
| -48% | -$56.7K |
|
1146
Clear Channel Outdoor Holdings
CCO
$1.23B
| $50.3K | ﹤0.01% |
41,931
-3,539
| -8% | -$5.22K |
|
1147
Nu Holdings
NU
$65.5B
| $50K | ﹤0.01% |
+10,494
| New | +$46.8K |
|
|
FRBK
1148
DELISTED
Republic First Bancorp Inc
FRBK
| $47.4K | ﹤0.01% |
34,873
-83,815
| -71% | -$164K |
|
|
SGMO
1149
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $27.6K | ﹤0.01% |
15,671
-2,405
| -13% | -$6.86K |
|
1150
Relmada Therapeutics
RLMD
$503M
| $26.6K | ﹤0.01% |
11,750
-901
| -7% | -$3.11K |
|
Similar funds
VAI
Los Angeles Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Los Angeles Capital Management held 1,346 positions worth $22.5B, up 9.4% from $20.6B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Los Angeles Capital Management's Q1 2023 filing shows 164 new, 337 increased, 605 reduced and 194 closed positions. Its largest new stake was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M. The largest sale was Pfizer, an estimated $196M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.
- Los Angeles Capital Management's largest Q1 2023 buy was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M.
- Los Angeles Capital Management added most to Visa in Q1 2023, an estimated $426M increase.
- Los Angeles Capital Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $196M.
- Los Angeles Capital Management fully exited Regions Financial in Q1 2023, selling an estimated $50.4M.
- Los Angeles Capital Management's ten largest holdings make up 27% of its $22.5B portfolio in Q1 2023.
- Los Angeles Capital Management opened 164 new positions and closed 194 in Q1 2023.
- Los Angeles Capital Management's portfolio value rose 9.4% quarter-over-quarter to $22.5B.
Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.